Morepen Laboratories Limited
All news and filings related to Morepen Laboratories Limited.
View all news & filings- Low impact
Morepen Labs: Trading Window Closed Oct 1, 2026 for Q2 FY27 Results
Morepen Laboratories Limited will close its trading window from October 1, 2026, to consider and approve unaudited financial results for the quarter and half-year ended September 30, 2026. Designated persons and their relatives are restricted from trading until 48 hours after the results announcement.
Read the summary - Medium impact
Morepen Labs Submits First US ANDA for Sitagliptin Tablets USP
Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths. This move expands their CDMO capabilities into integrated finished dosage development. Approval is estimated within 24-36 months.
Read the summary - Medium impact
Morepen Labs 41st AGM: Key Resolutions Passed Including Dividend and Management Re-appointments
Morepen Laboratories Limited's 41st AGM on September 26, 2026, saw the passing of resolutions for annual accounts adoption and a ₹0.20 dividend. Key management changes included Mr. Sanjay Suri's appointment as MD and Mr. Sushil Suri's re-appointment as CMD. The medical devices business hive-off timeline was also extended.
Read the summary - Medium impact
Morepen Labs Holds 41st AGM, Approves Dividend & Key Management Changes
Morepen Laboratories Limited conducted its 41st AGM on September 26, 2026. The meeting approved the financial statements for FY26 and a final dividend of ₹0.20 per share. Key decisions included changes in management designations and extending the timeline for hiving off the Medical Devices Business.
Read the summary - Low impact
Morepen Labs receives 'Adequate' ESG rating from CRISIL
Morepen Laboratories Limited received an 'Adequate' ESG rating of 'CRISIL ESG 60' from Crisil ESG Ratings & Analytics. The rating was assigned independently by CRISIL based on publicly available information for fiscal year 2026.
Read the summary - Medium impact
Morepen Labs Completes Phase 1 Manufacturing Expansion Ahead of Schedule
Morepen Laboratories Limited has completed the first phase of its manufacturing capacity expansion ahead of schedule. The installed reactor capacity for API and CDMO has increased from 535 KL to 614 KL, strengthening its manufacturing readiness for CDMO supplies and API business.
Read the summary - Low impact
Morepen Labs: Newspaper Publication for 41st AGM Notice & Annual Report Dispatch
Morepen Laboratories Limited has completed dispatching the notice for its 41st AGM and the FY25-26 Annual Report. Newspaper publications detailing e-voting and book closure were made on September 3, 2026.
Read the summary - Medium impact
Morepen Labs Schedules AGM on Sep 26, Proposes ₹0.20 Dividend
Morepen Laboratories Limited will hold its 41st AGM on September 26, 2026, via video conference. A final dividend of ₹0.20 per equity share is proposed, with a record date of September 19, 2026. Remote e-voting begins September 23, 2026. The Annual Report for FY2025-26 is available online.
Read the summary - Medium impact
Morepen Labs announces 41st AGM on Sep 26, proposes ₹0.20 final dividend
Morepen Laboratories Limited will hold its 41st AGM on September 26, 2026, proposing a final dividend of ₹0.20 per share. Key proposals include director re-appointments and elevations, with Mr. Sanjay Suri becoming Managing Director and Mr. Sushil Suri continuing as Chairman & Managing Director. The company also seeks to extend the timeline for hiving off its medical devices business until the 42nd AGM.
Read the summary - Low impact
Morepen Labs Announces 41st AGM, Dividend, and Record Date
Morepen Laboratories Limited announced its 41st Annual General Meeting (AGM), dividend, and record date. Notices were published in Financial Express and Jansatta on August 26, 2026. The details are also available on the company's website.
Read the summary - Low impact
Morepen Labs subsidiary Morepen RX allots 2 Cr equity shares worth ₹20 Cr
Morepen Laboratories Limited's wholly-owned subsidiary, Morepen RX Limited, has allotted 2 Crore equity shares worth ₹20 Crore to the parent company via a rights issue. This allotment strengthens MRX's capital base. Morepen Laboratories now holds 2.70 Crore shares in MRX, maintaining its 100% ownership.
Read the summary - Low impact
Morepen Labs Publishes Q1 FY27 Un-audited Financial Results
Morepen Laboratories Limited published its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were approved by the Board on August 4, 2026, and published in Financial Express and Jansatta on August 5, 2026. The results are also available on the company's website.
Read the summary - Medium impact
Morepen Labs Q1FY27 Monitoring Report: Nil Deviation in QIP Proceeds Utilization
Morepen Laboratories' QIP proceeds of ₹200 crore have been utilized as per the offer document for Q1FY27. ₹4.46 crore was spent on manufacturing unit expansion. Working capital funding of ₹66.29 crore is fully utilized. Capex utilization timeline extended to March 31, 2027. Company faces ₹117.94 crore GST refund notice.
Read the summary - Medium impact
Morepen Labs Approves Q1 FY27 Results, Dividend, and CMD Re-appointment
Morepen Laboratories approved Q1 FY27 results, a record date of September 19, 2026, for a final dividend, and extension for hiving off its Medical Devices Business. Mr. Sushil Suri was re-appointed Chairman & Managing Director for three years from October 20, 2026. The 41st AGM is on September 26, 2026.
Read the summary - Medium impact
Morepen Labs Approves Q1 FY27 Results, Dividend Record Date, and CMD Re-appointment
Morepen Laboratories approved Q1 FY27 results. A dividend record date of September 19, 2026, was set. The Medical Devices Business divestment timeline was extended. Mr. Sushil Suri was re-appointed as CMD for three years from October 20, 2026. The 41st AGM is on September 26, 2026.
Read the summary - Medium impact
Morepen Labs Board Approves Q1 FY27 Results, Sets Record Date for Dividend, Reappoints CMD
Morepen Laboratories announced Q1 FY27 results with consolidated revenue at ₹570.13 crore. The board approved the dividend record date as September 19, 2026. Mr. Sushil Suri was re-appointed as Chairman & Managing Director for three years from October 20, 2026. The 41st AGM is on September 26, 2026.
Read the summary - High impact
Morepen Labs Q1 FY27 Revenue Surges 34% YoY to ₹575 Cr; PAT Jumps 394%
Morepen Laboratories reported its highest-ever quarterly revenue of ₹575.31 crore in Q1 FY27, up 34% YoY. EBITDA surged 207% to ₹87.72 crore, and PAT jumped 394% to ₹56.35 crore. The company's ₹825 crore CDMO mandate entered full commercialization, with ₹58 crore in dispatches completed. Export revenue grew 111% YoY.
Read the summary - High impact
Morepen Labs Q1 FY27: Revenue ₹575 Cr, EBITDA ₹87 Cr, PAT ₹56 Cr
Morepen Laboratories reported a record Q1 FY27 revenue of ₹575.31 crore, up 34% YoY. EBITDA surged 207% to ₹87.72 crore, with margins at 15.25%. PAT increased 394% to ₹56.35 crore. Export revenue grew 111%. The company is expanding manufacturing capacity to 1200 KL and sees its CDMO business as a key growth driver.
Read the summary - High impact
Morepen Labs Q1 FY27 Results: Profit Soars, Dividend Declared, CMD Reappointed
Morepen Laboratories reported its Q1 FY27 results, with a significant increase in profit. The board approved a dividend, setting the record date for September 19, 2026. Mr. Sushil Suri was reappointed as Chairman & Managing Director for three years, effective October 20, 2026. The 41st AGM is scheduled for September 26, 2026.
Read the summary - Low impact
Morepen Labs FZCO renamed to Morepen Labs FZE effective July 20, 2026
Morepen Laboratories Limited's wholly owned subsidiary, Morepen Labs - FZCO, has been renamed Morepen Labs FZE. The change is effective July 20, 2026, following its migration to Jebel Ali Free Zone (JAFZA). JAFZA issued relevant certificates on July 23, 2026.
Read the summary - Low impact
Morepen Labs Senior Management Personnel Resigns
Mr. Bhola Prasad, General Manager – Process Engineering & Technology Transfer at Morepen Laboratories Limited, has resigned effective July 6, 2026. The resignation is due to personal reasons and career growth aspirations outside the company.
Read the summary - High impact
Morepen Starts ₹825 Cr CDMO Supplies; ₹50 Cr Dispatch Completed in Q1FY26-27
Morepen Laboratories has begun commercial supplies for its ₹825 crore CDMO mandate, completing the first dispatch of ₹50 crore in Q1FY2026-27. The company expects to supply an additional ₹225 crore in Q2FY2026-27. Reactor capacity is set to reach 600 KL by end-Q2, expanding to 1,000 KL later.
Read the summary - High impact
Morepen Labs Q4 FY26 Results: Net Profit Up 48% YoY to ₹55.27 Cr
Morepen Laboratories reported audited standalone and consolidated financial results for Q4 FY26. Standalone net profit increased by 48% YoY to ₹55.27 crore, with total income at ₹1050.96 lakh. Consolidated net profit rose 48% YoY to ₹55.01 crore, with total income at ₹1065.67 lakh. The results were approved on May 26, 2026.
Read the summary - High impact
Morepen Labs Q4 FY26 Revenue Up 22% to ₹472 Cr; FY26 Revenue at ₹1703 Cr
Morepen Laboratories reported Q4 FY26 revenue of ₹472 crore, up 22% YoY. FY26 revenue reached ₹1703 crore, an 8% increase. API segment grew 17% and Medical Devices 31% in Q4. Commercial production commenced for a ₹823 crore mandate, with phased deliveries starting soon. The company aims to improve its EBITDA profile towards 20%+.
Read the summary - Medium impact
Morepen Labs Board Approves FY26 Results, Recommends Dividend
Morepen Laboratories approved FY26 audited results and recommended a final dividend of ₹0.20 per share. The company also amended a Business Transfer Agreement with subsidiary Morepen Medipath Limited, revising the 'Appointed Date' to April 1, 2026. Cost Auditors were re-appointed.
Read the summary - Medium impact
Morepen Labs: QIP Fund Utilization Report for Q4FY26 Shows No Deviation
Morepen Laboratories' QIP funds of ₹200 crore are being utilized as per the offer document. ₹27.88 crore of ₹41.44 crore allocated for medical device development remains unutilized, with an extended deadline of March 31, 2027. Working capital funding increased slightly to ₹66.29 crore. Profitability is subdued due to API margin compression.
Read the summary - Medium impact
Morepen Labs Secures ₹30 Crore Term Loan from Shinhan Bank
Morepen Laboratories Limited secured a ₹30 Crore unsecured term loan from Shinhan Bank. The loan has a 36-month tenure with a 7.60% interest rate and is guaranteed by the promoter. This adds to the company's existing outstanding loans of ₹182.62 Crore.
Read the summary - High impact
Morepen Labs Secures Fourth Consecutive USFDA Inspection with Zero Observations
Morepen Laboratories Limited's Masulakhana facility successfully passed a USFDA inspection on April 17th, 2026, with zero observations (NIL Form 483). This is the fourth consecutive such clearance for the company, reinforcing its commitment to global quality standards and enhancing its credibility with regulators and customers.
Read the summary - Low impact
Morepen Labs Publishes Special Window Notice for Physical Share Transfer
Morepen Laboratories Limited has announced a special window for the transfer and dematerialisation of physical shares. This initiative is in compliance with a SEBI circular and will be publicized bi-monthly until February 4, 2027. The announcement was published on April 15, 2026.
Read the summary - Low impact
Morepen Labs: Trading Window Closed From April 1 for Financial Results
Morepen Laboratories Limited will close its trading window from April 1, 2026, for considering audited financial results for the quarter and fiscal year ending March 31, 2026. The window will reopen 48 hours after the results announcement.
Read the summary - Low impact
Morepen Labs Repays ₹99 Crore Credit Facility from Kotak Mahindra Bank
Morepen Laboratories Limited fully repaid its ₹99 crore credit facility from Kotak Mahindra Bank. The repayment, effective March 2, 2026, included a ₹79 crore working capital loan and a ₹20 crore cash credit limit. The bank is now processing the release of charged assets.
Read the summary - Medium impact
Morepen Labs Secures ₹30 Crore Working Capital Loan from KEB Hana Bank
Morepen Laboratories Limited secured an unsecured working capital term loan of ₹30 crore from KEB Hana Bank. The loan has a 3-year tenure with a 6-month moratorium and a 7.30% annual interest rate. Mr. Sushil Suri provided a personal guarantee.
Read the summary - High impact
Morepen Labs Secures ₹825 Crore Global CDMO Deal
Morepen Laboratories has secured an international CDMO contract worth approximately ₹825 crore (USD 91 million) from a leading global pharma major. The contract involves development and manufacturing services, with supplies expected to begin in 4-5 months and execution over 12-15 months. This marks an expansion into the CDMO segment.
Read the summary - High impact
Morepen Labs Secures ₹825 Crore Global CDMO Deal, Expands Manufacturing
Morepen Laboratories secured a multi-year CDMO mandate worth ₹825 crore from a global pharma major. Supplies are expected to start within 4-5 months, with execution through Q1 of the next financial year. This marks a significant expansion into the high-growth CDMO segment.
Read the summary - Medium impact
Morepen Labs Executes Rs 50 Crore Term Loan Agreement with Woori Bank
Morepen Laboratories Limited executed a loan agreement with Woori Bank for an unsecured term loan of ₹50 crore. The loan has a 3-year tenure with 8 quarterly repayments after a one-year moratorium. The interest rate is 7.40% p.a. Mr. Sushil Suri provided a personal guarantee. Outstanding loans were ₹137.70 crore.
Read the summary - Medium impact
Morepen Labs Secures ₹50 Crore Term Loan from Woori Bank
Morepen Laboratories Limited's Finance Committee approved a ₹50 crore unsecured term loan from Woori Bank on February 11, 2026. Loan agreements are expected to be executed shortly, with further disclosures to follow.
Read the summary - Low impact
Morepen Labs Publishes Q3 FY26 Unaudited Financial Results
Morepen Laboratories Limited published its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The results were approved by the Board on February 10, 2026, and published in Financial Express and Jansatta on February 11, 2026.
Read the summary - Medium impact
Morepen Labs QIP Fund Utilization: Rs. 167.65 Cr Utilized, Rs. 21.43 Cr Unutilized as of Dec 31, 2025
Morepen Laboratories Limited utilized ₹167.65 crore of its ₹200 crore QIP issue proceeds by December 31, 2025. ₹101.36 crore was spent on manufacturing unit expansion, with ₹21.43 crore remaining unutilized. Working capital funding of ₹66.29 crore is fully utilized. A GST refund notice of ₹117.94 crore is under a court stay.
Read the summary - Medium impact
Morepen Labs Q3 FY26: Gross Revenue Up 13% to ₹462 Cr
Morepen Laboratories reported Q3 FY26 gross revenue of ₹462 crore, a 13% increase year-on-year. The Pharma business revenue was stable at ₹285 crore, while Medical Devices revenue rose to ₹177 crore. Standalone PAT was ₹8 crore and consolidated PAT was ₹28 crore.
Read the summary - Medium impact
Morepen Labs Q3FY26 Results Approved: Unaudited Standalone & Consolidated Financials Reviewed
Morepen Laboratories Limited's Board approved unaudited standalone and consolidated financial results for Q3FY26 and the nine months ended December 31, 2025. The results were reviewed by the Audit Committee and auditors. The company operates in the pharmaceutical segment.
Read the summary - Low impact
Morepen Labs Reports Status on Physical Share Transfer Requests Under SEBI Special Window
Morepen Laboratories Limited received a report on physical share transfer requests under SEBI's special window (Jan 1-6, 2026). As of Jan 1, 2026, no requests were received, processed, approved, or rejected during this period.
Read the summary - Low impact
Morepen Labs Reports Status of Physical Share Transfer Requests for December 2025
Morepen Laboratories Limited reported no physical share transfer requests were received, processed, or approved in December 2025. The status update is in line with SEBI's special window for re-lodgement of physical shares.
Read the summary - Low impact
Morepen Labs gets stay from Himachal High Court on GST refund notice
Morepen Laboratories Limited received a stay from the Himachal Pradesh High Court on a Show Cause Notice regarding an alleged excess GST refund claim of ₹117.94 crore. The High Court's order, received on January 8, 2026, stays the operation of the notice, with no impact on the company's financials or operations.
Read the summary - Low impact
Morepen Labs: Trading Window Closes Jan 1 for Q3 FY26 Results
Morepen Laboratories Limited will close its trading window from January 1, 2026. This is to facilitate the consideration and approval of the unaudited financial results for the quarter and nine months ending December 31, 2025. Designated persons and their relatives are prohibited from trading during this period.
Read the summary - Medium impact
Morepen Laboratories Receives Show Cause Notice from GST Authority
Morepen Laboratories received a Show Cause Notice from GST Authority regarding an alleged excess GST refund claim of ₹117,94,03,452. The company will submit the required information.
Read the summary - Low impact
Report on transfer requests of physical shares re-lodged under special window
Morepen Laboratories reports on physical share transfer requests under SEBI's special window. No requests were received, processed, approved, or rejected during November 2025.
Read the summary - Low impact
Morepen Labs Announces Publication of Unaudited Financial Results
Morepen Labs published unaudited financial results for the quarter ended September 30, 2025, in Financial Express and Jansatta on November 15, 2025, following board approval on November 14, 2025.
Read the summary - Medium impact
Morepen Laboratories: QIP Fund Utilization Monitored, Capex Progress & Profitability Concerns Noted
Morepen Labs submitted its QIP fund utilization report for Q2FY26. No material deviation in fund use, but capex completion is delayed, and profitability declined due to API segment margin compression.
Read the summary - Medium impact
Morepen Laboratories Releases Q2 FY26 Investor Presentation with Mixed Financials
Morepen Laboratories released its Q2 FY26 investor presentation. Standalone revenue was ₹374 crore, with PAT at ₹14 crore. Consolidated PAT significantly increased to ₹41 crore, despite mixed revenue performance.
Read the summary - Medium impact
Morepen Labs Approves Unaudited Standalone & Consolidated Results for Quarter Ended Sep 30, 2025
Morepen Labs approves unaudited standalone & consolidated financial results for quarter ended September 30, 2025. The board also approved dividend of ₹0.20 per equity share which was already paid on September 22, 2025.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio